Avant Bio — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

RoosterBioroosterbio.comJul 2024SEC filingmedium confidence

RoosterBio supplies human mesenchymal stem/stromal cells (hMSCs), exosome systems, and cGMP media with built-in processes and protocols for companies and researchers developing cell therapy, gene therapy, and tissue engineering products.

Advanced ManufacturingBiotechMedical DevicesFrederick, US

Jon Rowley(Director)inTimothy Kelly(Executive Officer, Director)Margot Connor(Executive Officer, Director)Uplaksh Kumar(Chief Operating Officer)

BoardMartin Westberg(Director)Rob Carlson(Director)

Board seatDaniella Kranjac· per SEC Form D · $12M raise · filed Jul 2024

Co-investorsDynamk Capital Maryland TEDCO TEDCO Vanedge Capital Vanedge Capital Limited Partnership

Viricaviricabiotech.com in 𝕏May 2024SEC filingmedium confidence

Virica is a biotech company that develops small-molecule "Viral Sensitizers" which temporarily reduce host cell defenses during viral vector production to increase yield, quality, and scalability.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesOttawa, CA

Jean-Simon Diallo(Founder)inKen Newport(Executive Officer)inElla Korets-Smith(Executive Officer)in

Board seatDaniella Kranjac· per SEC Form D · filed May 2024

Co-investorsDynamk Capital

PL BioSciencepl-bioscience.com in 𝕏Aug 2024

PL BioScience develops human platelet-based cell culture media that promote cell growth, used in biotechnology research and cell culture applications.

BiotechNew Materials

Dr. Hatim Hemeda(Founder & CEO)

Co-investorsTechVision Fonds Better Ventures Central Llc Brightlands Venture Partners Seed Fonds Aachen

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.